Collagen Or Derivative Affecting Or Utilizing Patents (Class 514/17.2)
-
Patent number: 8809274Abstract: Disclosed is an adhesive hemostatic agent based on non-blood constituents including DOPA, able to strongly adhere to collagen fibers, and which comprises an antifibrinolytic agent in addition to an esterified atelocollagen which is non-immunogenic and may become positively charged thereon such that the adhesive hemostatic agent has no possibility of mediating particular diseases or viral infections (HIV, HCV, HBV, CMV, etc), unlike conventional agents comprising blood constituents, and readily binds to negatively charged platelets at high adhesive strength, thus inducing quick blood coagulation. Also, provided is a method for preparing the same.Type: GrantFiled: September 21, 2011Date of Patent: August 19, 2014Assignees: Dalim Biotech Co., Ltd., Industry-Academic Cooperation Foundation, Yongsei-UniversityInventor: Hwal Suh
-
Publication number: 20140228840Abstract: In one aspect, composite compositions are described herein. In some embodiments, a composite composition comprises an embolic agent and a plurality of nanoparticles dispersed in the embolic agent, wherein a portion of the nanoparticles are individually dispersed in the embolic agent.Type: ApplicationFiled: September 28, 2012Publication date: August 14, 2014Applicant: Wake Forest UniversityInventors: Joel L. Berry, David L. Carroll, Pierre H. Rolland
-
Publication number: 20140228297Abstract: An object of the present invention is to provide a preventive agent for atopic dermatitis and food products containing the agent. The present inventors conducted extensive studies and, as the result, found that atopic dermatitis can be prevented by orally ingesting collagen. The present invention provides a preventive agent for atopic dermatitis comprising collagen and food products containing the preventive agent for atopic dermatitis.Type: ApplicationFiled: April 16, 2014Publication date: August 14, 2014Applicant: LOTTE CO., LTD.Inventors: Hiroaki HIGUCHI, Atsushi NARISE, Kenji OSAWA, Katsumasa SHIMIZU, Masanori ITO
-
Publication number: 20140227235Abstract: The present invention relates to a medical composite biomaterial. More specifically, the present invention relates to a medical composite biomaterial including collagen and a hyaluronic acid derivative. Also, the present invention relates to a cartilage cell treating agent using the biomaterial and stem cells derived from a mammal umbilical cord. The biomaterial does not cause an immune reaction, has superior durability, and the cartilage cell treating agent comprising the biomaterial and the stem cells enables arthroscopic surgery, thereby reducing pain of the patient and effectively treat of degenerative arthritis and cartilage damage.Type: ApplicationFiled: July 11, 2012Publication date: August 14, 2014Applicant: CHA BIO & DIOSTECH CO., LTD.Inventors: Sun Mi Kim, Youngjun Lee, Yong Soo Choi
-
Publication number: 20140213525Abstract: Methods are provided for treating astigmatism in an eye of a patient. An axis of greater curvature of the eye is determined. A stiffening process is applied to a cornea of the eye in a pattern defined from the axis of greater curvature of the eye.Type: ApplicationFiled: January 28, 2014Publication date: July 31, 2014Applicant: The Cleveland Clinic FoundationInventors: William J. Dupps, Ibrahim Seven
-
Patent number: 8790699Abstract: Foam-formed collagen strands and methods for forming strands involve depositing a dispersed solution of an isolated cleaned, de-fatted, enzymatically-treated (or non-enzyme treated) human-derived collagen product having a preserved amount of its natural constituents into grooves of a grooved plate, and processing the dispersed collagen product to provide a foam-formed collagen strand. Foam-formed collagen strands may be processed into threads having a matrix of reticulated pores to conduct biological materials in and through the strand, the collagen of the collagen strand comprising isolated, enzymatically-treated human derived collagen having a preserved amount of its natural collagen constituents.Type: GrantFiled: April 23, 2010Date of Patent: July 29, 2014Assignee: Warsaw Orthpedic, Inc.Inventors: Nels Lauritzen, Lawrence A. Shimp, Brent Mitchell
-
Patent number: 8790698Abstract: Techniques for treating visceral or parietal membrane and tissue defects include the application of a collagen biomatrix to the defect to repair and regenerate a visceral or parietal membrane, for example in patients suffering tissue defects or undergoing visceral or parietal surgical treatment. Such approaches avoid persistent tissue leaks and their consequences such as fluid leaks and air leaks. The use of collagen biomatrix, optionally in conjunction with a fibrin sealant, an anti-adhesive, or both, can minimize tissue leaks or fluid leaks in injured patients suffering tissue defects or subjects undergoing surgery such as visceral or parietal resections and other operations.Type: GrantFiled: October 29, 2008Date of Patent: July 29, 2014Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Johann Odar, Raymond Nistor-Gallo, Laura Caliari
-
Patent number: 8785389Abstract: This invention relates to the production of biomaterials from polymeric collagen (PC) and its seeding with cells and other components of biomaterials. Polymeric collagen is isolated from tissue, suspended in an acidic solution, and then neutralized at low temperature. The neutralized suspension is then seeded with biomaterial components, such as cells, and the polymeric collagen aggregated to form a biomaterial comprising the biomaterial components. Polymeric collagen biomaterials produced as described herein may therefore be useful in a range of tissue engineering applications.Type: GrantFiled: July 16, 2010Date of Patent: July 22, 2014Assignee: UCL Business PLCInventors: Robert Brown, Burcak Alp, Hector Hadjipanayi
-
Publication number: 20140200531Abstract: Aspects of the present invention concern the discovery of a transdermal delivery composition that can deliver low, medium and high molecular weight pharmaceuticals and cosmetic agents. Embodiments include transdermal delivery compositions with therapeutic and cosmetic application, transdermal delivery devices for providing said transdermal delivery compositions to subjects in need thereof, and methods of making and using of the foregoing.Type: ApplicationFiled: December 19, 2013Publication date: July 17, 2014Applicant: JRX Biotechnology, Inc.Inventors: Frederick Jordan, Geoff E. Dolbear
-
Patent number: 8778883Abstract: A kit for producing a foamed biocompatible material includes a container configured to sustain a high pressure, and a tissue-repair composition placed in the container. The composition contains a biocompatible material, a liquid carrier, and a gas. The container has an internal pressure of greater than 1 atm and less than 250 atm, and includes a valve and a nozzle for releasing from the nozzle a foam formed of the composition upon opening the valve. Methods of producing and applying the biocompatible material are also disclosed.Type: GrantFiled: November 13, 2009Date of Patent: July 15, 2014Assignees: Industrial Technology Research Institute, National Taiwan University HospitalInventors: Chun-Jen Liao, Sheng-Hong Tseng, Huang-Chien Liang, Yi-Chun Su, Pei-Chi Hsu
-
Publication number: 20140193515Abstract: The present invention relates to methods of forming wound dressings from jellyfish collagen. A jellyfish tissue is provided, after which an acid is added to produce a collagen-salt solution. The solution is mixed to form a viscous colloidal gel, and a film or a film/fabric composite is created from the gel.Type: ApplicationFiled: March 12, 2014Publication date: July 10, 2014Applicant: Coll-Med, Ltd.Inventor: Samuel Angel
-
Publication number: 20140179612Abstract: The present invention provides recombinant proteins comprising transferrin that is linked to tumstatin or other antiangiogenic protein and methods for producing and using the same. The present invention also provides an expression system, a plasmid, and a cell that is capable of expressing such recombinant proteins and methods for producing and using the same.Type: ApplicationFiled: August 15, 2012Publication date: June 26, 2014Applicant: The Regents of the University of Colorado, a body CorporateInventors: Uday B. Kompella, Robert I. Scheinman, Puneet Tyagi
-
Patent number: 8758791Abstract: A highly compression resistant matrix is provided for implantation at or near a target tissue site beneath the skin. The matrix comprises a polymer and a ceramic skeleton. The compression resistance provides retention of a volume that facilitates bone regeneration.Type: GrantFiled: January 26, 2010Date of Patent: June 24, 2014Assignee: Warsaw Orthopedic, Inc.Inventor: William F. McKay
-
Patent number: 8758806Abstract: Human lubricating gels, methods and kits for delivering a therapeutic agent to a target tissue site beneath the skin of a patient utilizing human lubricating gel are provided, the human lubricating gel being capable of adhering to the target tissue site and comprising one or more biodegradable formulations containing an effective amount of the therapeutic agent. In various embodiments, the human lubricating gel is sprayable and hardens after contacting the target tissue site.Type: GrantFiled: January 23, 2012Date of Patent: June 24, 2014Assignee: Warsaw Orthopedic, Inc.Inventors: Susan J. Drapeau, Guobao Wei
-
Patent number: 8748579Abstract: Disclosed herein are a collagen-based matrix for use as a restorative material and a method for the preparation thereof. An atelocollagen dispersion is spread at a predetermined thickness over a plate and freeze-dried to form a porous collagen membrane. An atelocollagen dispersion is separately spread over a plate and pressurized to form a dense collagen membrane. This is overlaid with the porous collagen membrane and immersed in an EDS solution in ethanol to crosslink the two membranes with each other. From the bilayer structure thus constructed, EDS is removed, followed by lyophilization and cutting into an appropriate size.Type: GrantFiled: April 15, 2009Date of Patent: June 10, 2014Assignee: Dalim Tissen Inc.Inventors: Seong-Ki Lee, Si-Nae Park, Sang-Hee Bae
-
Publication number: 20140147400Abstract: The present invention relates to the use of fish skin as novel industrial source of collagen. Advantageously, said skin is obtained after the filleting or cutting of the fresh fish and frozen immediately after filleting/cutting, thus guaranteeing a very good quality of the base material, both from the bacteriological standpoint and from the standpoint of the native property of the protein.Type: ApplicationFiled: January 31, 2014Publication date: May 29, 2014Inventors: Jamilah Bakar, Umi H. Razali, Dzulkifly M. Hashim, Awis Q. Sazili, Kaur Harvinder
-
Publication number: 20140147494Abstract: An aligned polymer article including substrates, wherein the substrates are not covalently bonded to the aligned collagen and a method of forming such articles wherein substrates are mixed with a polymer in solution to form a polymer-substrate mixture. The mixture is placed in an electrochemical cell and a voltage is applied to the cell generating a pH gradient, wherein the polymer aligns in the cell and migrates to the isoelectric plane of the polymer solution.Type: ApplicationFiled: November 8, 2013Publication date: May 29, 2014Inventor: Xingguo CHENG
-
Publication number: 20140142041Abstract: The disclosure describes collagen constructs comprising anticancer agents, preferably, platinum, and related methods.Type: ApplicationFiled: March 15, 2013Publication date: May 22, 2014Inventor: Thomas J. Koob
-
Patent number: 8729020Abstract: The invention relates to compositions comprising vasoactive intestinal peptide (VIP) or fragments thereof, and the use of such compositions in the treatment of aortic fibrosis and other associated conditions.Type: GrantFiled: April 6, 2010Date of Patent: May 20, 2014Assignee: Vectus Biosystems Pty LtdInventor: Karen Annette Duggan
-
Patent number: 8722626Abstract: The present invention is related to the use of secretagogue peptides repeatedly administered as part of a pharmaceutical composition that prevent and eradicate the deposition of pathological fibrotic material in parenchymal tissues of internal organs like the liver, lungs, esophagus, small intestine, kidneys, blood vessels, joints, and other systemic forms of cutaneous fibrosis of any etiopathogenesis. Additionally, these peptides prevent and eradicate deposition of amiloid and hyaline materials in any of their correspondent chemical forms and tissue manifestations in the brain, cerebellum, blood vessels, liver, intestines, kidneys, spleen, pancreas, joints and the skin, among others. By this way, cellular, tissular and organ dysfunctions generated by these depositions are corrected. The peptides of the present invention are infiltrated or topically applied, contributing to prevent and eradicate keloids and hypertrophic scars in the skin, derived as sequelae of burns and other cutaneous trauma.Type: GrantFiled: June 1, 2011Date of Patent: May 13, 2014Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Jorge Berlanga Acosta, Danay Cibrian Vera, Diana Garcia Del Barco Herrera, Gerardo Enrique Guillén Nieto, José Suarez Alba, Ernesto Lopez Mola, Manuel Selman-Housein Sosa, Mariela Vazquez Castillo
-
Patent number: 8716227Abstract: A graft prostheses (11), materials and method for implanting, transplanting, replacing, or repairing a part of a patient. The graft prosthesis includes a purified, collagen-based matrix structure removed from a submucosa tissue source. The submucosa tissue source is purified by disinfection and removal steps to deactivate and remove contaminants, thereby making the purified structure biocompatible and suitable for grafting on and/or in a patient.Type: GrantFiled: October 31, 2007Date of Patent: May 6, 2014Assignee: Cook Biotech IncorporatedInventors: William A. Cook, Michael C. Hiles, Thomas G. Kozma, Umesh H. Patel
-
Publication number: 20140113012Abstract: The present invention provides compounds and compositions for the amelioration of arthritis and joint injuries by inducing mesenchymal stem cells into chondrocytes.Type: ApplicationFiled: March 26, 2012Publication date: April 24, 2014Applicant: THE SCRIPPS RESEARCH INSTITUTEInventors: Peter Schultz, Laure Bouchez
-
Patent number: 8703174Abstract: A pet supplement includes a joint preserving and joint rebuilding composition comprising chicken collagen type II, glucosamine hydrochloride and chondroitin sulfate, a vitamin composition comprising vitamins C, D and K, a mineral composition comprising calcium, magnesium, zinc, copper, manganese and boron, a herbal anti-oxidant cofactor blend comprising citrus bioflavonoids, red grapes anthocyanins, turmeric rhizome, boswellia resin and fennel seed. Each of these ingredients is intimately mixed into the pet supplement and orally delivered to the pet in the form of a segment, paste or powder having a size and weight or other dosage measuring feature adjusted in accordance with the pet's weight. A synergistic action between these ingredients preserves and rebuilds the pet's joints, and is nutritionally beneficial for the pet.Type: GrantFiled: September 15, 2006Date of Patent: April 22, 2014Assignee: I did It IncInventor: Marni Markell Hurwitz
-
Publication number: 20140107035Abstract: The present invention has demonstrated for the first time that orally administered type I collagen (CI) induced tolerance to CI in patients suffering from systemic sclerosis (SSc) and ameliorated clinical manifestations of the disease. Accordingly, the present invention provides methods of treating a fibrosing disease by oral administration of a tissue protein, for example, collagen, derived from the tissue undergoing fibrosis.Type: ApplicationFiled: December 13, 2013Publication date: April 17, 2014Applicant: The University of Tennessee Research FoundationInventors: Arnold E. Postlethwaite, Andrew H. Kang
-
Publication number: 20140107036Abstract: Improved methods are provided for the recombinant synthesis of collagen, particularly collagen VII, in host cell, and for therapeutic delivery of the same. The recombinant collagen is produced in a host cell that has increased levels of prolyl-4-hydroxylase, relative to basal cell levels. The collagen produced by the methods of the invention has increased numbers of modified proline residues, relative to a recombinant collagen produced in a host cell having basal levels of prolyl-4-hydroxylase. The increased proline modification provides for a collagen having increased stability, including increased in vivo stability.Type: ApplicationFiled: April 26, 2012Publication date: April 17, 2014Inventors: M. Peter Marinkovich, Alfred T. Lane, Jayakumar Rajadas
-
Publication number: 20140105852Abstract: A process for making cross-linked polysaccharide gels, particularly cross-linked hyaluronic acid gels, under basic conditions. The resulting gels possess improved degradation characteristics, and are useful in a variety of medical and cosmetic applications.Type: ApplicationFiled: December 26, 2013Publication date: April 17, 2014Applicant: Ultraceuticals R&D Pty. LimitedInventors: Simone Charlotte Vonwiller, Geoffrey Kenneth Heber
-
Publication number: 20140105856Abstract: System and methods for isolation of collagen and other fibrous tissue from adipose tissue are described herein. The method of the present invention isolates the collagen from adipose tissue by sonication. The tissue to be sonicated is placed in a container or a flow cell transparent to ultrasound waves. After sonication the sonicated material is filtered out through the bottom of the flow cell and the sonicated collagen is trapped in the filter, which may be taken for further processing. The isolated collagen can then be combined with a suitable carrier for re-injection to correct various tissue defects such as wrinkles, to form a carrier for the stem cells, a filler, and matrix for new collagen production by injecting into the desired area of the host.Type: ApplicationFiled: June 22, 2012Publication date: April 17, 2014Inventor: Stephen Schendel
-
Publication number: 20140105876Abstract: The invention relates to a ceramic biocomposite for bone regeneration, having a pH range of between 6.5 and 8.5, with an initial plasticity that allows the biocomposite to be easily moulded in situ and to set after 7 minutes, meaning that it can remain at the indicated location during the healing process. In addition, the biocomposite has demonstrated an ability to stimulate bone formation in hard-to-heal wounds. The material can act alone or in combination with other types of bone graft such as autografts, homografts or xenografts which act as a vehicle, as a binding material for endosseous prostheses or as a covering for endosseous implants or prostheses.Type: ApplicationFiled: March 27, 2012Publication date: April 17, 2014Applicant: UNIVERSIDAD AUTONOMA DE OCCIDENTEInventors: Sandra Arce Guerrero, Carlos Humberto Valencia
-
Patent number: 8691766Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Example of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.Type: GrantFiled: February 8, 2012Date of Patent: April 8, 2014Assignee: Brown University Research FoundationInventors: Justin R. Fallon, Beth A. McKechnie, Michael Rafii, Hilliary Creely, Mark A. Bowe, Alison R. Amenta, Mary Lynn Mercado, Hiroki Hagiwara
-
Patent number: 8691951Abstract: It is an object of the present invention to provide a Type I-Type IV collagen hybrid gel, which maintains characteristics of a Type IV collagen and is superior in gel strength. It is the Type I-Type IV collagen hybrid gel obtained by mixing 100 to 500 parts by mass of the Type I collagen having fibrosis ability, relative to 100 parts by mass of the Type IV collagen having gelling ability. A three-dimensional structure is formed, where a membrane-like substance by the Type IV collagen is formed onto a fibrous substance by the Type I collagen, so as to be able to provide cell culture environment approximate to a basement membrane of a living body.Type: GrantFiled: February 14, 2011Date of Patent: April 8, 2014Assignees: Japan Institute of Leather Research, Osaka UniversityInventors: Shunji Hattori, Yoh-ichi Koyama, Hitomi Fujisaki, Kiyotoshi Sekiguchi, Sugiko Futaki, Ryoko Sato
-
Publication number: 20140088007Abstract: The present invention relates to a novel composition comprising an implant, scaffold or construct bound to a biological or chemical moiety. The bound moiety has the ability to bind to a component of the extracellular matrix of biological tissue, allowing the implant to be bound to the biological tissue in a short period of time after implantation. The invention also relates to the use and manufacture of this novel composition, as well as a novel use for the protein CNA.Type: ApplicationFiled: March 6, 2013Publication date: March 27, 2014Applicants: NEW YORK SOCIETY FOR THE RUPTURED AND CRIPPLED MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY, THE TEXAS A&M UNIVERSITY SYSTEM, THE TRUSTEES OF PRINCETON UNIVERSITYInventors: New York Society for the Ruptured and Crippled Maintaining the Hospital for Special Surgery, The Trustees of Princeton University, The Texas A&M University System
-
Publication number: 20140088502Abstract: An injector system for delivery of a pharmacological agent to biological tissue having a plurality of needles arranged in an array, a plurality of reservoirs configured to receive a pharmacological composition therein, the reservoirs being in fluid communication with a respective one of the plurality of needles, a pneumatic pressure source, a pneumatic drive system that is configured to induce a first discharge of the pharmacological composition out of the reservoirs and needles in a plurality of delivery modes, agent delivery volume control means for controlling volume of the pharmacological composition discharged from the needles, and a control system having actuation control means for controlling said pneumatic drive system. The control system is programmed to control the delivery modes.Type: ApplicationFiled: September 19, 2013Publication date: March 27, 2014Inventors: Robert G. Matheny, Bret Herscher, Michael Perry
-
Patent number: 8680123Abstract: Disclosed herein are substituted N-Aryl pyridinone fibrotic inhibitors and/or collagen infiltration modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.Type: GrantFiled: October 29, 2012Date of Patent: March 25, 2014Assignee: Auspex Pharmaceuticals, IncInventors: Thomas G. Gant, Sepehr Sarshar
-
Patent number: 8679470Abstract: Disclosed are compositions comprising crosslinked hyaluronic acid gels, preferably vinyl sulfone cross-linked hyaluronic acid known as hylan B gel, for use in topical cosmetic and dermatological formulations. The hylan B gel in these formulations provides prolonged delivery of incorporated substances to the surface of the skin, to provide a hydrated film on the surface of the skin, and to provide a substantive and compatible film on the skin.Type: GrantFiled: November 28, 2008Date of Patent: March 25, 2014Assignee: LuroMed LLCInventors: Adelya K. Leshchiner, Nancy E. Larsen, Edward G. Parent
-
Publication number: 20140079749Abstract: Compositions and methods for administering collagen to a human subject have been developed. The collagen-containing lipid vesicles of the invention provide a delivery system for human collagen which eliminates problems associated with chemical and physical instability of the collagen as well as immune responses to non-human collagen.Type: ApplicationFiled: November 15, 2013Publication date: March 20, 2014Inventor: MARK A. PINSKY
-
Publication number: 20140073575Abstract: Prolyl and lysyl hydroxylases isolated from Mimivirus are described. These are able to hydroxylate collagen. Isolated nucleic acids coding for the mentioned hydroxylases are incorporated into suitable vectors and used to express these hydroxylases in host cells, e.g. E. coli. Furthermore a method of manufacturing hydroxylated collagen in a host cell is described. The hydroxylases and the recombinantly expressed hydroxylated collagen are useful in clinical settings and biotechnology applications.Type: ApplicationFiled: March 21, 2012Publication date: March 13, 2014Applicant: UNIVERSITAET ZUERICH PROREKTORAT MNWInventors: Thierry Hennet, Christoph Rutschmann, Kelvin Luther
-
Publication number: 20140072613Abstract: The described invention provides compositions, dressings and methods for treating a cutaneous scar in a subject. The compositions of the derived invention contains a pharmaceutical composition comprising a therapeutic amount of a Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK2) inhibitor comprising an MK2 polypeptide inhibitor or a functional equivalent thereof, and a pharmaceutically acceptable carrier.Type: ApplicationFiled: March 14, 2013Publication date: March 13, 2014Inventors: Cynthia Lander, Caryn Peterson, Colleen Brophy
-
Publication number: 20140066379Abstract: A recombinant vector, transgenic fish egg using the same and biomaterial using the same are applied to provide a transgenic fish that secreting recombinant human procollagens or collagens, and further to provide the biomaterial having the recombinant human procollagens or collagens and extract the recombinant human procollagens or collagens from the part(s), having the recombinant human procollagens or collagens, of the transgenic fish.Type: ApplicationFiled: August 28, 2013Publication date: March 6, 2014Applicant: Body Organ Biomedical Corp.Inventors: Chuian-Fu Ken, Hong-Yi Gong, Jen-Leih Wu, Horng-Ji Lai, Chien-Cheng Lin, Yong-Guei Chen, Cheng-Hung Chou
-
Publication number: 20140065245Abstract: A novel dietary supplement and methods for manufacturing the said dietary supplement are disclosed for promoting healthy cartilages, connective tissues and bones. The dietary supplement of the present invention comprises glucosamine hydrochloride, collagen, and other dietary ingredients. Some ingredients of the dietary supplement of the present invention help to maintain the functions of cartilages, connective tissues and bones. Some ingredients of the dietary supplement of the present invention also exhibit anti-inflammatory properties. Overall, these ingredients of the dietary supplement are beneficial to the health of human and other animals.Type: ApplicationFiled: August 30, 2012Publication date: March 6, 2014Applicant: NATURE'S SELECT INTERNATIONAL INC.Inventor: Pai-Ying Hsu
-
Publication number: 20140056964Abstract: Methods of promoting wound healing in a subject is disclosed. The method include applying a Granzyme B (Granzyme B) inhibitor to the wound. The wound may be a skin wound. The Granzyme B inhibitor may be comprised of nucleic acids, or peptides, including but not limited to antibodies, or small molecules.Type: ApplicationFiled: December 6, 2011Publication date: February 27, 2014Applicant: THE UNIVERSITY OF BRITISH COLUMBIAInventors: Paul R. Hiebert, Darryl A. Knight, David J. Granville, Wendy A. Boivin, Dawn M. Cooper
-
Patent number: 8658218Abstract: A composition for treating damaged tissue and promoting healthy tissue growth, healing and tissue regeneration, wherein the composition comprises an extracellular matrix compound, a surface-active lipid, one or more enantiomericaily pure L-amino acids or glycine, a hydrophilic surfactant with a high HLB, as well as vitamins, minerals or trace elements. Not only does it maintain good health, but the components are non-intrusive, bio-safe, non-coalescent and can mimic normally occurring stem-cells within a body. When applied to diseased tissues, the subject compositions can stimulate, facilitate, and accelerate protein synthesis for the regeneration of diseased organs and tissues. The healing efficacy of these tissue components gives us further appreciation of the protective action of human tissue over and above and other than the immune protective system or perhaps an integral component part of the immune system.Type: GrantFiled: February 8, 2012Date of Patent: February 25, 2014Assignee: Immunopath Profile, Inc.Inventor: Leonard S. Girsh
-
PROCOLLAGEN CARBOXY-TERMINAL PROPEPTIDES AS A TARGET AND TREATMENT FOR ANGIOGENESIS RELATED DISEASES
Publication number: 20140044736Abstract: The present invention relates to the field of angiogenesis. More specifically, the present invention provides methods and compositions for modulating angiogenesis. In a specific embodiment, a method for modulating a blood vessel in a subject in need thereof comprising contacting a cell of the subject with a procollagen carboxy-terminal propeptide, a biologically active fragment or mimetic thereof, thereby modulating the blood vessel.Type: ApplicationFiled: March 8, 2012Publication date: February 13, 2014Applicant: The Johns Hopkins UniversityInventor: Hans-Joerg Gerg Hammers -
Publication number: 20140045761Abstract: Methods and devices for determining the healing status of wounds, in particular of chronic wounds are provided. Also provided are kits comprising the diagnostic devices, and methods of wound diagnosis and treatment using the diagnostic devices and methods. A diagnostic apparatus (device) for monitoring wounds that exude a wound fluid and determining whether said wounds would be responsive to treatment with wound therapy such as oxidized cellulose therapy is also provided along with kits comprising the diagnostic apparatus and a wound dressing. Furthermore, methods of prognosing and treating wounds that exude a wound fluid are also provided.Type: ApplicationFiled: January 31, 2012Publication date: February 13, 2014Applicant: Systagenix Wound Management IP CO. BVInventor: Molly Gibson
-
Patent number: 8648042Abstract: A pharmaceutical polymer and a method for quenching free radicals is described. The pharmaceutical polymer comprises a glycopeptide covalently bound to an aminothiol moiety. The pharmaceutical polymer and method can be applied before or after the occurrence of radiation exposure.Type: GrantFiled: May 30, 2012Date of Patent: February 11, 2014Assignee: Taiwan Hopax Chems. Mfg. Co., Ltd.Inventors: Chau-Hui Wang, Chia-Hung Chen, Jing-Yi Chen, Chih-Wei Hsu
-
Patent number: 8642728Abstract: This invention relates to the finding that collagen peptides bind to the osteoclast-associated receptor (OSCAR) and stimulate the activation and/or differentiation of OSCAR expressing cells, such as osteoclasts and osteoclast precursor cells. Collagen peptides are described which may be useful in the modulation of the differentiation and/or activation of OSCAR expressing cells, for example in the treatment of bone defects and disorders characterized by altered differentiation and/or activation of OS-CAR expressing cells.Type: GrantFiled: October 6, 2009Date of Patent: February 4, 2014Assignee: Cambridge Enterprise Ltd.Inventors: John Trowsdale, Alexander Barrow, Richard Farndale
-
Publication number: 20140030309Abstract: This invention provides disrupted cartilage products, methods of manufacturing disrupted cartilage products, and methods of treating a subject comprising administering a cartilage product. The cartilage products are manufactured by a method comprising disrupting a collagen matrix, e.g. to produce a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic.Type: ApplicationFiled: July 11, 2013Publication date: January 30, 2014Applicant: Osiris Therapeutics, Inc.Inventors: Dana Sue Yoo, Jin-Qiang Kuang, Jaime Paden, Scott A. Maxson, Alla Danilkovitch, Erasmo Lopez, Samson Tom
-
Publication number: 20140031295Abstract: The present disclosure provides methods of treating epidermolysis bullosa, and/or preventing, preventing the progression of, or delaying the onset of one or more symptom associated with scarring, e.g., of blisters, in subjects with epidermolysis bullosa through chronic systemic administration of collagen 7.Type: ApplicationFiled: July 19, 2013Publication date: January 30, 2014Applicants: LOTUS TISSUE REPAIR, INC., UNIVERSITY OF SOUTHERN CALIFORNIAInventors: Mei CHEN, David WOODLEY, Mark de Souza
-
Publication number: 20140023714Abstract: The invention relates to a hemostatic composition in powder form comprising collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen, and at least one monosaccharide, and optionally, at least one compound selected from coagulation factors and glycosaminoglycans. The invention further relates to a method for preparing such composition, and to a unit comprising such composition and a spraying device.Type: ApplicationFiled: April 26, 2012Publication date: January 23, 2014Applicant: BIOM'UPInventors: Christian Gagnieu, Patricia Forest, Sylvain Picot
-
Patent number: 8628572Abstract: Provided herein is an endothelial scaffold comprising, consisting of, or consisting essentially of decellularized corneal stroma. In some embodiments, the scaffold has cultured endothelial cells seeded thereon. Methods of treating a patient in need of corneal endothelial transplant are also provided, including implanting the scaffold as described herein onto a cornea of the patient (e.g., by deep keratectomy).Type: GrantFiled: February 25, 2010Date of Patent: January 14, 2014Assignee: Wake Forest University Health SciencesInventors: Shay Soker, J. Koudy Williams, Patrick Laber, Margaret Greven, Keith A. Walter
-
Publication number: 20140011737Abstract: The present invention features compositions and methods for treating and preventing a metabolic syndrome featuring the collagen triple helix repeat containing-1 (Cthrc1) protein.Type: ApplicationFiled: July 3, 2013Publication date: January 9, 2014Applicant: MAINE MEDICAL CENTERInventor: Volkhard Lindner